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Attempted and achieved post-treatment parenthood, with or without use of assisted reproduction techniques (ARTs), was assessed
in Hodgkin’s lymphoma survivors treated from 1971–1998, aged below 50 (females) or 65 (males) at diagnosis, aged 18 to 75 at
survey. Four treatment groups were constructed: radiotherapy only, low -, medium - and high gonadotoxic chemotherapy (with or
without radiotherapy in the three chemotherapy groups). Using Kaplan–Meier estimates, log-rank tests and Cox regression analyses,
factors influencing post-treatment parenthood were investigated, with birth of the first child after treatment as the end point. Forty-
five per cent (120/269) of males and 50% (91/184) of females reported attempted post-treatment parenthood. Of these, 76 (63%)
males and 68 (75%) females had a child without use of ARTs. In addition 10 males and one female achieved post-treatment
parenthood with use of ARTs. Treatment group was significantly associated with post-treatment parenthood, with highest
probabilities after radiotherapy only and low gonadotoxic chemotherapy. In univariate analyses, age at diagnosis was a significant
factor related to post-treatment parenthood in females.
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Most previous studies on fertility in Hodgkin’s lymphoma
survivors (HLSs) have addressed post-treatment spermatogenesis
and secondary amenorrhea (Viviani et al, 1985, 1991; Hill et al,
1995; Behringer et al, 2005). Although the number of achieved
pregnancies and childbirths is sometimes reported in small series
(Schilsky et al, 1981; Whitehead et al, 1983; Bonadonna et al, 1984;
Anselmo et al, 1990), the selection of survivors attempting
parenthood is not reported, with a few exceptions (Aisner et al,
1993; Hodgson et al, 2006).
We therefore aimed to determine rates for attempted and
achieved post-treatment parenthood with or without use of
assisted reproduction techniques (ARTs), in HLSs treated at the
Rikshospitalet-Radiumhospitalet Medical Center (RRMC).
PATIENTS AND METHODS
Patients
During 1971—1998, a total of 1567 HL patients were registered in
the lymphoma database of the RRMC. A questionnaire survey
concerning various late effects and quality of life was performed
from 2001 to 2002 among consecutive HLSs fulfilling the following
criteria: treatment from 1971 to 1998, age 18–75 years at the time
of survey, no relapse after 1 January 1999, no secondary cancer
(except cutaneous basal cell carcinoma) and valid postal address.
The present study addresses the survivors’ achievement of post-
treatment parenthood, as evidenced in the survey, and excluded
females aged above 50 years and males above 65 years at diagnosis.
Patients diagnosed with a secondary non-Hodgkin’s lymphoma
(NHL) were included as their treatment options were similar to
those with relapsed HL. For supplementary information on
fertility, the female responders from 2002 were contacted again
in 2005. The present study includes male responders from the
survey of 2002 and female responders from the survey of 2005
(with their reproduction as of 2002) (Figure 1).
Treatment principles
The treatment strategies of HL at the RRMC have been described
previously (Abrahamsen et al, 1996, 1997; Holte et al, 1996;
Aurlien et al, 1998; Blystad et al, 2001a, 2001b) and are
summarized in Table 1a and b. From 1985 to 1990, primary
chemotherapy with MVPP/ChlVPP was gradually replaced by
ABOD or EBVP for limited disease. At relapse, patients were
treated with noncross-resistant chemotherapy, or – from 1990 –
with high-dose chemotherapy with autologous stem cell support
(HDT). Fractionated total body irradiation (TBI) with high-dose
cyclophosphamide was used as a conditioning regimen for HDT
until 1995, and was thereafter changed to chemotherapy only
(BEAC/BEAM) (Blystad et al, 2001a, 2001b).
In stage I and II patients, mantle field and inverted Y field
radiotherapy dominated up until 1997 with target doses of 41.4Gy
(1.8Gy 23) given alone or after chemotherapy. If possible, the
standard inverted Y field was modified (to unilateral L-field or
para-aortic field) in order to reduce the gonadal doses. Patients
with stage III and IV received radiotherapy to areas of initial bulky
Received 2 January 2007; revised 23 February 2007; accepted 1 March
2007; published online 3 April 2007
*Correspondence: Dr CE Kiserud, Unit for long term outcome,
Department of Clinical Cancer Research, Rikshospitalet-Radiumhospitalet
Medical Center, 0310 Oslo, Norway.
E-mail: cecilie.essholt.kiserud@radiumhospitalet.no
British Journal of Cancer (2007) 96, 1442–1449
& 2007 Cancer Research UK All rights reserved 0007– 0920/07 $30.00
www.bjcancer.com
E
p
i
d
e
m
i
o
l
o
g
ytumours or residual masses after chemotherapy. Gonadal shielding
was routinely used, reducing gonadal doses from 0.6 to 0.1–0.2Gy
during mantle field irradiation. Inverted Y field resulted in
testicular doses of 0.6–0.9Gy. In the 1970s, medial transposition
of the ovaries was offered to young patients. In these patients, the
shielded ovaries received about 3Gy when treated with inverted Y
field (Jetne, RRMC, 1972, unpublished data).
For the purpose of this study, the total treatment for each
patient as registered in the lymphoma database was summarised.
Chemotherapy was sub-grouped according to the expected
gonadotoxicity of the regimens used: low (LowChem), medium
(MedChem) and high (HighChem) gonadotoxicity (Viviani et al,
1985; Howell and Shalet, 2001; Behringer et al, 2005; American
Society of Clinical Oncology et al, 2006; Hodgson et al, 2006).Two
sub-groups of radiotherapy were defined: supradiaphragmatic
radiotherapy (SupRad) only and infradiaphragmatic radiotherapy
with or without supradiaphragmatic irradiation (InfRad). In
preliminary analyses, no differences were observed between these
two subgroups of radiotherapy as to attempted or achieved post-
treatment parenthood. Therefore, one treatment variable (treat-
ment) was constructed discriminating patients with radiotherapy
only from those having chemotherapy with low, medium and high
gonadotoxicity (with or without radiotherapy).
Assisted reproduction techniques
The Norwegian legislation on ARTs has been rather restrictive.
Since 1980, Norwegian male patients have had the option for
pretreatment semen cryopreservation, with ARTs performed as
intrauterine insemination (IUI) in the early 1980s and as in vitro
fertilisation (IVF) since 1988. Intracytoplasmatic sperm injection
(ICSI) has been offered since 1995. Pretreatment cryopreservation
of fertilised oocytes has been offered since 1988, but has never
been used by any cancer patient. Use of donated semen, but not
oocytes, is allowed.
Questionnaire, data management and ethical
considerations
The questionnaire included instruments on fatigue and quality of
life as reported previously (Hjermstad et al, 2005, 2006), in
addition to questions concerning reproduction relevant for
the present analysis. We assessed attempted and achieved
73 no answer 12 did not want
to participate
355 eligible males contacted 
in 2002
269 responders
included in this 
study
270 responders 
one not answering the
fertility questions
247 eligible females contacted in 2002
34 no answer Seven did not want
to participate
206 responders 
11 dead 195 eligible contacted
in 2005
184 responders
included in this
study
11 no answer 
Figure 1 Flow charts of male and female HLSs who met the inclusion
criteria for the present study.
Table 1 Treatment of Hodgkin’s lymphoma at the RRMC 1970-1998
Chemotherapy Radiotherapy (RT) Dose and fractions of radiotherapy
(a) Treatment principles
Stage I & II
1970–1980 RT only Extended fields MF/Inv Y 2Gy 20
1980–1988 With risk factors: four MVPP/ChlVPP
before RT
Extended fields MF/Inv Y 2Gy 20, from 1982 1.8Gy 23
1988–1997 With risk factors: 2–4 EBVP before RT Extended fields MF/Inv Y 1.8Gy 23
Stage III and IV
1970–1985 Eight MVPP/ChlVPP To bulky tumor or residual mass TNI to
some stage III patients until 1980
2Gy 20
1985–1991 Eight ChlVPP or 8 ABOD/ChlVPP
(alternating)
To bulky tumor or residual mass 2Gy 20 or 1.8Gy 23
1992–1998 8 ABVD To bulky tumor or residual mass 2Gy 20 or 1,8Gy 23
Low Medium High
(b) Chemotherapy and expected gonadal toxicity
ABO(V)D ChlVPP ChlVPP
EBVP MVPP MVPP
Medium if p4 courses High if 44 courses
CHOP High-dose chemotherapy with autologous
stem cell support BEAC/BEAM
MIME
MF¼mantle field; RRMC¼Rikshospitalet-Radiumhospitalet Medical Center; Inv Y¼inverted Y field; TNI¼total nodal irradiation. For details on chemotherapy: Aurlien et al
(1998); Diehl (2001); Mills et al (1995).
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children, calendar years of childbirths and use of ARTs (without
differentiation between IUI, IVF and ICSI and without recording
the use of hormone therapy alone for inducing ovulation). Data
from the questionnaire survey were merged with the lymphoma
database of the RRMC.
Informed consent was obtained from all responders. The
participants were informed in the invitation letter that the survey
included various late effects after cancer treatment and quality of
life. The Regional Committee for Medical Research Ethics, Health
Region South, Norway and the Institutional Review Board at the
RRMC approved the study.
Statistics
Data were analysed using descriptive statistics (SPSS 13.0 for PC).
Factors influencing attempted post-treatment parenthood were
analysed by cross-tables and w
2 tests for categorical variables, and
by t-test for continuous variables. Binary logistic regression
analyses were carried out with attempted post-treatment parent-
hood regarded as the dependent factor.
In patients attempting post-treatment parenthood Kaplan–
Meier estimates, log-rank tests and Cox regression analyses
evaluated the probability of becoming parents without use of
ARTs, with the first post-treatment childbirth as the end point. The
observation time for post-treatment parenthood started 8 months
after start of last treatment and ended at the date of first childbirth,
or 30 June 2002 (the cutoff date of the study), whichever occurred
first. For Kaplan–Meier analyses, patients were categorised into
three groups according to age at diagnosis: (I): p20.0 years, (II):
20.1–30.0 years, (III): 30.1–40.0 years at diagnosis. In Cox
regression analyses, age at diagnosis was used as a continuous
variable because of lack of proportionality in the Kaplan–Meier
curve. Variables significant in univariate analyses were included
as covariates in multivariate analyses together with clinical
parameters of major interest. P-values less than 0.05 (two-tailed)
were considered significant, and 95% confidence intervals are
given.
RESULTS
Patients’ characteristics
Of the 1567 HL patients registered in the database from this period,
the 602 eligible for the present study were contacted by mail (811
were dead at the time of the survey, 107 had a second cancer
diagnosis, 24 had relapse after 1999, 19 were excluded because
of age criteria and four had no valid postal address). There were
269 male and 184 female responders (a response rate of 75%
(Figure 1)). No differences in observation time, initial stage,
principal therapeutic group and relapse rates were observed
for responders and non-responders. Responding males were
Table 2 Patients characteristics
Male Female
All N¼269%
are within this
group
Attempted PtP
n¼120% are
within this
group
Not attempted
PtP n¼149%
are within this
group
All N¼184%
are within this
group
Attempted PtP
N¼91% are
within this
group
Not attempted
PtP N¼93% are
within this
group
Age at diagnosis
a(years)
b 29.4 (14.6–62.2) 24.4 (16.0–38.3) 34.5 (14.6–62.2) 26.1 (9.1–49.0) 23.0 (9.1–37.1) 31.1 (13.4–49.0)
Age at survey
a (years) 47.0 (22.0–73.9) 42.0 (25.0–61.0) 51.9 (22.0–73.9) 43.8(20.9–72.9) 39.3 (20.9–62.9) 49.1 (22.9–72.9)
Observation time
a (years)
c 14.6 (2.8–30.6) 16.2 (2.8–30.0) 13.3 (3.5–30.6) 15.6 (2.9–34.1) 15.6 (3.1–34.1) 15.9 (2.9–29.3)
Parenthood at diagnosis
d 127 (47%) 30 (26%) 97 (65%) 83 (45%) 23 (25%) 60 (65%)
Childless at diagnosis 132 (49%) 86 (72%) 46 (31%) 98 (53%) 67 (74%) 31 (33%)
Stage I and II 170 (63%) 70 (58%) 100 (67%) 112 (61%) 57 (63%) 55 (59%)
Stage III and IV 99 (37%) 50 (42%) 49 (33%) 72 (39%) 34 (37%) 38 (41%)
Relapse 36 (13%) 10 (8%) 26 (17%) 18 (10%) 7 (8%) 11 (12%)
Treatment
Rad 73 (27%) 34 (28%) 39 (26%) 48 (26%) 27 (30%) 21 (23%)
LowChem 72 (27%) 33 (28%) 39 (26%) 37 (20%) 22 (24%) 15 (16%)
MedChem 63 (23%) 23 (19%) 40 (27%) 63 (34%) 31 (34%) 32 (34%)
HighChem 61 (23%) 30 (25%) 31 (21%) 36 (20%) 11 (12%) 25 (27%)
HDT 8 (3%) 5 (4%) 3 (2%) 8 (4%) 1 (1%) 7 (7%)
Radiotherapy
(7chemotherapy) N¼238% are
within this group
N¼105% are
within this group
N¼133% are
within this group
N¼160% are
within this group
N¼83% are
within this group
N¼77% are within
this group
SupRad 177 (74%) 82 (78%) 95 (71%) 125 (79%) 66 (80%) 59 (77%)
InfRad 61 (26%) 23 (22%) 38 (29%) 35 (21%) 17 (21%) 18(23%)
Pelvic radiotherapy
e
(7supradiaphragmatic
radiotherapy)
48 (20%) 16 (15%) 32 (24%) 22 (13%) 8 (10%) 14 (18%)
HDT¼high-dose chemotherapy with autologous stem cell support; HighChem¼high gonadotoxic chemotherapy (7radiotherapy); InfRad¼infradiaphragmatic radio-
therapy7supradiaphragmatic radiotherapy; LowChem¼low gonadotoxic chemotherapy (7radiotherapy); MedChem¼medium gonadotoxic chemotherapy (7radiotherapy);
PtP¼post-treatment parenthood; Rad¼radiotherapy only; SupRad, supradiaphragmatic radiotherapy only.
aMedian (range).
bSignificant factor with regard to attempted PtP.
In both males and females, Po0.001 in univariate analyses (t-test), Po0.001 in multivariate analyses.
cObservation time: time from diagnosis added 8 months, to time of the
survey.
dSignificant factor with regard to attempted PtP. In both males and females, Po0.001 in univariate analyses (w
2 test), P¼0.027 in multivariate analyses.
ePelvic
radiotherapy: inverted Y-, L-, Sacrum(skeletal)- fields, total body irradiation (TBI).
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years (median)), whereas the opposite was the case in females (26.1
vs 32.3 years (median)).
Of all responders, 86% were o40 years at diagnosis. The median
observation time from last treatment to survey was 15 years (range
3–34 years), with 62% of the patients diagnosed before 1989, and
61% treated with radiotherapy and chemotherapy. At the time of
diagnosis, 46% had at least one child (127 males had 1–7 children
and 83 females had 1–6 children) (Table 2).
Attempted post-treatment parenthood
Ninety-one (50%) females and 120 (45%) males reported to have
attempted post-treatment parenthood, all aged below 40 years
at diagnosis. In both univariate and multivariate analyses, low
age and childlessness at diagnosis were the only variables
associated with post-treatment attempts of parenting. Twenty-
three females reported not to have attempted post-treatment
parenthood because they were convinced to be infertile
after treatment; three of them were treated with radiotherapy
only, 17 treated with medium or high and three with low
gonadotoxic chemotherapy. The comparable number for males
is not known.
Post-treatment parenthood
At the time of the survey, 68 females (75%) and 76 males (63%)
who had attempted post-treatment parenthood had been success-
ful without use of ARTs. The 10-year probability of post-treatment
parenthood was 59% in females and 56% in males (no significant
difference between genders) (Figure 2, Table 3). In patients
childless at diagnosis, the 10-year probabilities of post-treatment
parenthood were 58% in females and 54% in males (data not
shown).
Females aged below 30 years at diagnosis were significantly
more likely to achieve post-treatment parenthood compared to
older females. After 10 years, the group aged 20.1–30.0 at
diagnosis had the highest probability of post-treatment parent-
hood: 77%, compared to 50% in the youngest group and 18% in
the oldest group. Fifteen years after diagnosis, the comparable
figures were 89% in the group aged 20.1–30.0 at diagnosis and
85% in those aged p20 years at diagnosis. Only two of 11 females
older than 30 years at diagnosis achieved motherhood, one after
mantle field irradiation only and one after four EBVP followed by
mantle field irradiation. In males, there was no significant
difference between the age groups.
Males, but not females, diagnosed after 1988 had significantly
improved probability of achieving post-treatment parenthood
compared to those diagnosed before 1989, with 10-year probabi-
lities of 81 vs 43%. In males, but not in females, stage I/II was
followed by significantly higher probability of post-treatment
parenthood, compared to stage III/IV.
In males, there was a significantly higher probability of post-
treatment fatherhood after radiotherapy only and after chemo-
therapy of low gonadotoxicity compared to chemotherapy with
medium or high gonadotoxicity. The 10-year probabilities of
achieving post-treatment parenthood in the various groups were
71 (Rad), 85 (LowChem), 35 (MedChem) and 18% (HighChem).
In females, a significantly higher probability of achieving post-
treatment motherhood was observed after radiotherapy only
compared to chemotherapy with either medium or high gonado-
toxicity. In addition, a comparable difference was seen between
those treated with low and high gonadotoxic chemotherapy. The
10-year probabilities were 82% (Rad), 55% (LowChem), 51%
(MedChem) and 27% (HighChem).
Treatment with highly gonadotoxic chemotherapy did not
exclude the possibility of having a child without the use of ARTs.
Of 11 females attempting motherhood after highly gonadotoxic
chemotherapy, six were successful; all six were aged o25 years at
diagnosis. The five patients who did not achieve post-treatment
parenthood were 30–36 years at diagnosis (Table 4). Ten of 28
males attempting fatherhood after highly gonadotoxic chemother-
apy became fathers. Two of these achieved children spontaneously
4 years after HDT with BEAM as conditioning regimen, one of
them after having a first post-treatment child with the use of
pretreatment cryopreserved semen.
Of all irradiated patients, 76% had received supradiaphragmatic
radiotherapy only. Of 16 males and eight females who had
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Figure 2 Achieved post-treatment parenthood (PtP) in male and female
HLSs among those who attempted PtP, according to: (A) Gender. Males
n¼112, females n¼90. (B and C) Age at diagnosis. (I) p20 years (n¼33
females, n¼19 males), (II) 20.1–30.0 years (n¼46 females, n¼73 males),
(III) 30.1–40.0 years (n¼11 females, n¼20 males). (D and E) Calendar
year of diagnosis. o1989: diagnosis before 1989 (n¼72 males, n¼58
females), 41989: diagnosis in/after 1989 (n¼40 males, n¼32 females).
(F and G) Treatment Rad¼radiotherapy only (n¼34 males, n¼27
females), LowChem¼low gonadotoxic chemotherapy (n¼33 males,
n¼22 females), MedChem¼medium gonadotoxic chemotherapy
(n¼17 males, n¼30 females), HighChem¼high gonadotoxic chemother-
apy (n¼28 males, n¼11 females).
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inverted Y field; four: mantle field/inverted Y field; three: mantle
field/L-field) and five females (four: L-field; one: inverted Y field
preceded by oophoropexy) were successful.
In the Cox regression multivariate analysis, post-treatment
parenthood was significantly associated with treatment group in
both males and females. In addition, the period of diagnosis was a
significant factor in males.
Table 3 10 years probability of achieving PtP among those who attempted, excluding those achieving PtP with the use of assisted reproduction
techniques
Males
N¼112
Females
N¼90
Variable
10 years
prob. of PtP
(%) 95% CI
P-value
(log-rank test)
P-value
(Cox analysis)
10 years
prob. of PtP
(%) 95% CI
P-value
(log-rank test)
P-value
(Cox regression
analysis)
All 56 47–65 59 48–69
Age at diagnosis (years)
(I) p20.0 53 30–76 50 33–67 0.035 vs II 0.001
vs III
(II) 20.1–30.0 58 47–69 NS Ns
a 77 65–89 0.001 vs III Ns
a
(III) 30.1–40.0 57 35–79 18 0–41
Period of diagnosis
o 1989 43 32–55 o0.001 0.024 59 46–71 Ns Ns
X1989 81 68–93 58 40–76
Stage
Stage I and II 65 54–76 0.02 Ns 64 51–77 Ns Ns
Stage III and IV 42 27–57 50 33–67
Treatment 0.001 0.007
Rad 71 55–86 0.012 vs MedChem
o0.01 vs
HighChem
82 67–96 0.02 vs
MedChem 0.003
vs HighChem
LowChem 85 72–98 Ns vs Rad 0.02 vs
MedChem
o0.001 vs
HighChem
55 34–77 Ns vs Rad Ns vs
MedChem 0.048
vs HighChem
MedChem 35 13–58 51 33–69
HighChem 18 4–32 27 1–54
HighChem¼high gonadotoxic chemotherapy; lowChem¼low gonadotoxic chemotherapy; MedChem¼medium gonadotoxic chemotherapy; NS¼not significant; PtP¼post-
treatment parenthood; Rad¼Radiotherapy only
aAge at diagnosis as continuous variable in Cox regression analysis. Treatment: variable discriminating patients treated with
radiotherapy only from those having low, medium or high gonadotoxic chemotherapy.
Table 4 Children conceived by female HLSs treated with high gonadotoxic chemotherapy, for those who had attempted post-treatment parenthood
(N¼11)
Patient
no.
Year of
diagnosis
Age at
diagnosis
(years) Chemotherapy Radiotherapy (RT)
Achieved
PtP
Age at birth of first
child post-
treatment (years)
No of children
post-treatment
1 1976 9 Six MVPP SupRad
a+Paraaortic
field
Yes 24 Three
2 1979 18 Six MVPP SupRad Yes 29 Two
3 1988 17 Six ChlVPP 2 ABOD SupRad Yes 27 Two
4 1976 16 Six MVPP SupRad+Para-aortic
field
Yes 33
b Two
5 1981 23 Eight ChlVPP No RT Yes 32 Two (twins)
6 1988 19 Eight ChlVPP SupRad Yes 28 One
7 1988 36 Eight ChlVPP No RT No
8 1990 35 HDT
c SupRad No
9 1978 31 Six MVPP SupRad No
10 1971 32 Eight MVPP8 CCNU
po
Th10-12 3200 rtg/10
days
No
11 1978 30 Six MVPP SupRad+Paraaortic
field
No
aSupRad: supradiaphragmatic radiotherapy.
bFirst child after RT only at 18 years, relaps at 19 years, second child at age 33 years.
cHDT: high-dose chemotherapy with autologous
stem cell support.
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Thirteen men used ARTs with pretreatment cryopreserved semen,
with 10 becoming fathers. Two women used IVF/ICSI, with one of
them giving birth to one child.
Thus, at the end of the observation time, 69 (76%) of the females
and 85 (71%) of the males who had attempted post-treatment
parenthood had become biological parents after treatment, females
having a mean of 1.83 children (range 1–4) and males 1.73
children (range 1–5) post-treatment.
In addition, three males achieved fatherhood with use of donor
sperm cells, whereas one female had used oocyte donation (in
another Nordic country) without success. Four females and 11
males had adopted a total of 24 children (range 1–3).
DISCUSSION
Our study is the first to investigate long-term post-treatment
parenthood in a large series of consecutive HLSs. About 47% of the
HLSs in this study had attempted post-treatment parenthood.
Young age and childlessness at time of diagnosis were significantly
associated with attempts to conceive children after treatment. Of
those who had attempted post-treatment parenthood, 68% became
parents spontaneously. In addition, 10 males became fathers with
use of pretreatment cryopreserved semen and one female
conceived with use of ARTs. In multivariate analyses, type of
treatment was significantly associated with achievement of post-
treatment parenthood in both genders with highest probabilities
after radiotherapy only and low gonadotoxic chemotherapy. In
addition, an independent and significantly higher success rate was
observed in males diagnosed after compared to before 1989.
Several studies have dealt with post-treatment gonadal function
in HLSs, most of them with the end point of secondary
amenorrhoea, spermatogenesis mirrored by sperm count analyses
and the level of serum FSH (Viviani et al, 1985; Viviani et al, 1991;
Hill et al, 1995; Behringer et al, 2005). For males, these analyses
are a relatively appropriate parameter of fertility, whereas regular
post-treatment menstruation does not equal ovulation and the
possibility of pregnancy. Some authors have reported the number
of childbirths achieved in HLSs, but often in small series (Schilsky
et al, 1981; Whitehead et al, 1983; Bonadonna et al, 1984; Anselmo
et al, 1990), and rarely with those attempting post-treatment
parenthood as a denominator (Aisner et al, 1993; Hodgson et al,
2006).
Compared to these reports, our study has several methodo-
logical strengths besides its large size: our end point is the first
post-treatment childbirth. Secondly, we relate our end point to the
number of patients reported having attempted parenthood. For
male HLSs, the proportion of 45% who reported attempted
parenthood is comparable to that observed in two studies of
testicular cancer survivors (TCSs), where 31 and 39%, respectively,
had tried to father a child following treatment (Rieker et al, 1990;
Brydoy et al, 2005).
However, our number of HLSs who have attempted post-
treatment parenthood is probably underestimated for several
reasons. Firstly, only surviving patients reported their attempts at
parenthood. In studies on future plans for paternity in TCSs, 67%
could not exclude post-treatment fatherhood at the time of
diagnosis and 56% of cancer survivors responded that they would
like to have a child in the future, both numbers being higher than
in our study (Aass and Fossa, 1988; Schover et al, 1999). The
difference may in part be owing to psychological mechanisms in
those patients who did not succeed in having children, and
expressing that they did not want children may thus be a part of a
coping strategy. Furthermore, we have not systematically assessed
the reasons why individual patients did not attempt to have
children nor how hard the others tried to become a parent. This
note of caution is supported by answers from 23 females who
stated that they had not attempted post-treatment motherhood
because they were convinced of being infertile after cancer
treatment. Similar attitudes might be considered in females with
premature ovarian failure and in males after intensive treatment.
Reported rates of parenthood after treatment for cancer will
depend on selection criteria. In the present study, of those who
had attempted post-treatment parenthood, 68% conceived children
spontaneously. As the proportion of patients who reported to have
attempted parenthood may be underestimated, our reproduction
rates may be too favourable. A study of 43 premenopausal female
and 51 male HLSs attempting conception after treatment reported
a significantly higher frequency of achieved pregnancies in females
than in males, 81 and 49% respectively. The higher pregnancy rate
in females may have been overestimated because HLSs with early
menopause may have been excluded from the study (Aisner et al,
1993). The importance of selection bias is emphasised by the
figures of a registry-based study from our group, showing a
20-year probability of first post-treatment childbirth of 8% in
female and 28% in male lymphoma patients aged 15–45 years at
diagnosis, if all patients treated at the RRMC are included in the
denominator (Fossa and Magelssen, 2004). The relatively high
grade of success in achievement of post-treatment parenthood in
our study may also be explained by the high proportion of patients
(62%) with initial stage I/II and only 12% treated for relapse.
In both males and females, achievement of post-treatment
parenthood was associated with treatment, with the type and
intensity of chemotherapy being most important. This corre-
sponds to earlier studies on male fertility after treatment for HL,
with higher rates of preserved fertility after treatment with ABVD-
like regimens compared to MOPP-like regimens (Viviani et al,
1985; Anselmo et al, 1990; Viviani et al, 1991; Hill et al, 1995). Two
male patients spontaneously fathered children after HDT. A recent
report found post-treatment conceptions in 7% of males after
HDT for HL and NHL, but neither reported the use of ARTs nor
attempts of post-treatment parenthood (Carter et al, 2006). Only a
small proportion of the HLSs in this study used their pretreatment
cryopreserved semen, which has also been shown for other cancer
survivors (Ragni et al, 2003). However, 10 of 13 males successfully
achieved fatherhood with their cryopreserved semen, which is
more promising than in TCSs (Magelssen et al, 2005).
Earlier reports have shown that female post-treatment fertility
depends on the degree of gonadotoxicity of the treatment given
and age at diagnosis (Schilsky et al, 1981; Whitehead et al, 1983;
Bonadonna et al, 1984; Behringer et al, 2005). In a recent
publication, the 12-month pregnancy rate was 70% in 36 female
HLSs attempting pregnancy after treatment with ABVD, with no
significant difference compared to the control group (n¼29)
(Hodgson et al, 2006). In our study, age at diagnosis in females was
a significant factor associated with post-treatment parenthood in
univariate analysis. Age determines the remaining oocyte reserve
(Faddy et al, 1992), so the probability of sufficient oocyte reserve
decreases with increasing age.
No differences were found in post-treatment parenthood after
supradiaphragmatic radiotherapy only compared to infradia-
phragmatic radiotherapy with or without supradiaphragmatic
irradiation. However, almost 80% of the irradiated patients had
received supradiaphragmatic radiotherapy only, and the group of
HLSs who had attempted post-treatment parenthood after infra-
diaphragmatic radiotherapy was too small for valid statistical
comparison. As shown previously, successful pregnancies are
possible even after pelvic irradiation if oophoropexy has been
performed before inverted Y field irradiation (Le et al, 1976) or the
radiation field did not include both ovaries.
The improved probability of post-treatment parenthood in
males diagnosed after 1989 compared to before 1989 is as expected,
owing to changes in the treatment of HL in late 1980s with
introduction of fertility-saving treatment as less gonadotoxic
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attitudes towards life after treatment for HL and a more optimistic
view among health professionals with regard to having children
after cancer treatment in the latter period may also have
contributed to the increased paternity rate.
Our study has some limitations: we do not know at what
time after treatment the HLSs started attempting parenthood,
how seriously they attempted this goal or the fertility status
of our patient’s partners. Finally, we assume that each male
HLS who reported spontaneous post-treatment fatherhood is
the biological father of the child. Exclusion of patients with
relapse after 1999 or a second cancer from the survey and
the lack of relevant information in deceased patients may have
led to loss of information about patients trying to have children in
the years between initial treatment and relapse, second cancer or
death.
Information on fertility issues is important in clinical oncolo-
gical practice, and fertility-saving tasks should be discussed with
patients at risk of post-treatment infertility. Females should
be informed that both the treatment and their age at treatment
influence their fertility potential. Females aged above 30 years at
diagnosis are at high risk of becoming infertile. They constitute a
subgroup for whom cryopreservation of ovarian tissue should be
considered. As males have the opportunity for pretreatment
cryopreservation of semen and as spermatogenesis recovers in
most of them, their potential infertility after treatment is easier to
deal with.
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